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The analytical performances of the RAPIDEC CARBA NP® (bioMérieux) and the β-CARBA® (Bio-Rad) tests were
evaluated for the rapid detection of any known type of carbapenemases in Enterobacteriaceae. An international
collection of 149 enterobacterial isolates comprising 111 Carbapenemase-Producing Enterobacteriaceae (CPE)
and 38 non-carbapenemase producers was used. CPE included 32 carbapenemase producers of class A (18
KPC-2, 1 FRI-1, 5 SME and 8 IMI), 33 of class B (13 NDM, 11 VIM and 9 IMP) and 46 of class D (15 OXA-48, 14
OXA-181, 10 OXA-204, 3 OXA-232 and 4 OXA-162). The RAPIDEC CARBA NP® and the β-CARBA® tests were
performed in strict accordance to the manufacturer's instructions and results were read within 2 h and 30 min,
respectively. RAPIDEC CARBA NP® detected 104/111 CPE isolates compared to 72/111 for the β-CARBA® test.
The overall sensitivity and speciﬁcity were 93.7% and 100%, respectively, for the RAPIDEC CARBA NP® test, and
64.9% and 90%, respectively, for the β-CARBA® test. The β-CARBA® test failed to detect all the non-KPC class A
carbapenemases (14/14) and most (24/31) of the OXA-48-like producers (OXA-162, OXA-181, OXA-204 and
OXA-232), and detected 1/1 OXA-163 and 1/1 OXA-405 as carbapenemase producers whereas these enzymes
are rather deﬁned as non carbapenemases. RAPIDEC CARBA NP® test exhibited better performances
than those of the β-CARBA® test and conﬁrmed to be a reliable tool for the detection of CPE, especially for
OXA-48-like producers.
1. Introduction
The emergence and rapid dissemination of Carbapenemase-
Producing Enterobacteriaceae (CPE) during the last decade represents
the most worrisome event in the escalating antibiotic resistance crisis
(Nordmann et al., 2011) as CPE have been reported in numerous noso-
comial outbreaks worldwide. Most importantly, related infections can
be treated only by a few remaining therapeutic options (Canton et al.,
2012). Hence, rapid detection of CPE is of paramount importance for
the timely choice of the appropriate antibiotic therapy and for the im-
plementation of measures to prevent outbreaks.
Carbapenem resistance may arise from either (i) a concomitant
reduced permeability of the outer membrane and an overexpression
of enzymes with very low carbapenemase activity (e.g. extended-
spectrumbeta-lactamases and cephalosporinases) or (ii) the expression
of enzymes with signiﬁcant carbapenemase activity, deﬁned as
carbapenemases (Nordmann et al., 2012a). A large variety of acquired
carbapenemases has been reported worldwide in CPE. The most preva-
lent carbapenemases belong to the Ambler class A (KPC), class B (VIM,
IMP, and NDM) and class D (OXA-48 and OXA-48-like) (Albiger et al.,
2015).
Nowadays several methods are available for the rapid detection of
carbapenemase producers including: (I)molecular techniques to identi-
fy the most common carbapenemase genes (Findlay et al., 2015), (II)
the MALDI-TOF technology that allows the detection of carbapenem
degradation products (Hrabak et al., 2013), (III) a recently developed
electrochemical assay that allows the detection of carbapenemase-
producers (Bogaerts et al., 2016), (IV) immunochromatographic assays
detecting KPC, IMP-like, OXA-48 and OXA-48-like β-lactamases
(Glupczynski et al., 2016; Kitao et al., 2011) and (V) colorimetric assays
relying on the color change of a pH indicator to detect carbapenemase
activity (CARBA NP test (Nordmann et al., 2012b) and copies or de-
rivatives (Compain et al., 2016; Noel et al., 2016; Pires et al., 2013)).
Abbreviations: CPE, Carbapenemase-producing Enterobacteriaceae; MALDI-TOF,
Matrix-assisted laser desorption/ionization-time-of-ﬂight mass spectrometer; ESBL,
Extended-spectrum β-lactamases.
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which should be cited to refer to this work.
Here, we compared the performances of two commercially-available
colorimetric assays, the RAPIDEC® CARBA NP and the recently devel-
oped β-CARBA® test, by using a common panel of CPE.
2. Materials and methods
2.1. Strain collection
A collection of 149 clinical enterobacterial isolateswas used to assess
the performances of the RAPIDEC® CARBA NP (bioMérieux, La Balme-
les-grottes, France) and the β-CARBA® (Bio-Rad, Marnes-la-Coquette,
France) tests. All the strains were characterized for their β-lactamase
content by PCR and sequencing of the corresponding genes. The clinical
isolates ofworldwide originwere recovered fromvarious clinical samples
(sputum, blood cultures, urines, gut ﬂora, etc.) and consisted in 38
carbapenemase-negative isolates and 111 CPE. The carbapenemase-
negative isolates included 18 extended-spectrum β-lactamases (ESBL)
producers (CTX-M,OXA-163, OXA-405 andGES-1), 13 isolates possessing
plasmid-encoded or chromosomally-encoded overproducing AmpC, and
7 wild-type carbapenem-susceptible isolates. The CPE comprised 18
KPC producers, 1 FRI-1 producer, 5 SME producers, 8 IMI producers, 13
NDM-1 producers, 11 VIM producers, 9 IMP producers, 14 OXA-48 pro-
ducers and 31 OXA-48 like producers (Table 1).
2.2. Antibiotic susceptibility testing
Etest strips (bioMérieux) were used to determine the minimum
inhibitory concentrations (MICs) of meropenem and ertapenem. Results
were interpreted according to the EUCAST guidelines (http://www.
eucast.org/ast_of_bacteria/). The breakpoints for susceptibility/resistance
of meropenem and ertapenem were ≤2/N8 μg/ml and ≤0.5/N1 μg/ml,
respectively.
2.3. RAPIDEC® CARBA NP test
The RAPIDEC® CARBA NP was performed with colonies collected
from URISelect™ 4 plates (Bio-Rad) after 16 hours of incubation at
37 °C. The tested bacteria were taken with the extremity of a stick pro-
vided in the kit and resuspended in well C of the RAPIDEC® CARBA NP
kit to obtain a turbidity corresponding to that of the control. Results
were interpreted by multiple operators in a blinded manner after 2 h
of incubation in accordancewith the interpretation's guidelines. Results
were considered positive in case of color shifts from red to yellow, to
orange or to red-orange.
2.4. β-CARBA® test
The β-CARBA® test was performed using a 1 μl loop full with colo-
nies grown for 16 hours at 37 °C on URISelect™ 4 plates, as indicated
in the kit's manual. As recommended in the interpretation's guidelines,
resultswere read blindly bymultiple interpreterswithin 30min of incu-
bation. Results were considered positive in case of color changes from
yellow to clear orange, to red or to purple.
3. Results
3.1. Performances of the RAPIDEC® CARBA NP and β-CARBA® tests
Of the 149 tested isolates, 111 were CPE. RAPIDEC® CARBA NP
yielded positive results for 104 out of the 111 CPE isolates, while the
β-CARBA® test yielded positive results for only 72/111 isolates. Sensi-
tivity and speciﬁcity of the RAPIDEC® CARBA NP test were 93.7% and
100%, respectively, values that are in good agreement with those indi-
cated in the manufacturer's speciﬁcations (speciﬁcity 97.8% and sen-
sitivity 97.8%). By contrast, the sensitivity and speciﬁcity of the β-
CARBA® test were 64.9% and 90%, respectively, which are signiﬁcantly
inferior to those reported in the kit's speciﬁcations (speciﬁcity 89.4%
and sensitivity 97.8%).
3.2. Detection of the ambler class a, B and D type carbapenemases
Among the Ambler class A type carbapenemase producing isolates,
all the 18 KPC-2 producers were correctly assigned by both the
RAPIDEC® CARBA NP and β-CARBA® tests. However, while RAPIDEC®
CARBA NP test correctly identiﬁed the FRI-1 (1/1), SME (4/4) and IMI
(8/8) producers as carbapenemase producers, the β-CARBA® test failed
to detect all of them. All the Ambler class B producers (13 NDM, 11 VIM
and 9 IMP) were correctly assigned by both the RAPIDEC® CARBA NP
and β-CARBA® tests, in accordance with the results obtained by others
(Compain et al., 2016; Dortet et al., 2015a; Noel et al., 2016). Similar re-
sults were obtained with the 15 Ambler class D OXA-48 producers,
whose carbapenemase production was correctly assigned by both
tests. Contrasting results were instead observed with the remaining
Ambler class D carbapenemase producers. While RAPIDEC® CARBA NP
detected carbapenemase production of 24/31 OXA-48 like producers
(14 OXA-181, 10 OXA-204, 3 OXA-232 and 4 OXA-162), only 6/31
were correctly detected by the β-CARBA® test. Of note, extension of
the incubation time to 2 hours signiﬁcantly increased the number of
OXA-48-like carbapenemases correctly detected by the β-CARBA® test
(19/31) and therewith the sensitivity of the assay (76.6%), consistent
with previous observations (Compain et al., 2016). Also, use of larger
bacterial inocula (approximately double the initial amounts) did also
positively impact on the detection of OXA-48-like carbapenemases by
using the CARBA® test (data not shown). However, whether the use
of a higher bacterial inoculum might negatively affect on the overall
speciﬁcity of the β-CARBA® test was not investigated.
4. Discussion
4.1. Interpretation of the results
Several works have investigated the analytical performances of
RAPIDEC®CARBANP and have reported different sensitivities in detect-
ing CPE, ranging from 90.2% to 99% (Bernabeu et al., 2017; Dortet et al.,
2015a; Hombach et al., 2015; Kabir et al., 2016; Noel et al., 2016; Poirel
and Nordmann, 2015). On the other hand, with the exception of the
work carried out by Noël et al., where they report a value of 84% (Noel
et al., 2016), the sensitivity of the RAPIDEC® CARBA NP test is always
close to 100%. By contrast, only threeworkshave so far assessed the per-
formances of the β-CARBA® test in detecting CPE, reporting discordant
sensitivity values of 85.1% (Bernabeu et al., 2017), 85.4% (Compain et al.,
2016) and 97.3% (Noel et al., 2016), while the speciﬁcity values appear
more consistent, being 92.7%, 96% and 97.7%, respectively. The evalua-
tion of the analytical performances of such tests is notoriously affected
by the distribution of the carbapenemase types in the tested collection
of CPE, and most importantly by the proportion of OXA-48-like
carbapenemase producers, which are known to be more difﬁcult to de-
tect. Here, a large number of OXA-48-like producers (41% of the tested
CPE) was included to assess more accurately the sensitivity of the as-
says, but also to take into account the growing proportion of this
group of enzymes in many parts of the world and in particular in
Europe, as reported in a recent survey on the epidemiology of CPE con-
ducted in 38 European countries during 2014–2015 (Albiger et al.,
2015). Another factor that can inﬂuence the evaluation of the perfor-
mance of such assays is the way how doubtful results are categorized.
With regard to the RAPIDEC® CARBA NP test, divergence in the inter-
pretation of the results can occur when dealing with carbapenemase-
producing isolates causing a slight color change (red to orange), an ob-
servation classiﬁed as a weak positive result according to the
manufacturer's instructions but that operators may falsely consider as
negative results. Concerning the β-CARBA® test, ambiguity can derive








yellow, as the manufacturer's instructions clearly indicate that
positive results correspond to a color variation from yellow to
clear orange, red or violet. In the present work, we have evaluated
the results in strict observance of the manufacturers' instructions.
Also, doubtful results were considered negative and were not re-
peated as the purpose of this work was merely to evaluate the re-
liability of the tests based on the indications described in the
user's manuals.
Table 1
Detection of carbapenemase- and non-carbapenemase producing Enterobacteriaceaea.
RAPIDEC MIC (μg/ml)
β-lactamase type Species n CARBA NP® β-CARBA® ETP MEM
Carbapenemase positive strains
Ambler class A carbapenemases
KPC-2 E. coli 4 + + 0.25–0.75 0.19–0.75
E. coli 1 + + 0.75 0.38
K. pneumoniae 4 + + 0.32- N 32 0.5- N 32
K. pneumoniae 1 + + N32 N32
E. cloacae 4 + + 0.38–8 0.38–3
E. aerogenes 1 + + 3 2
S. marcescens 3 + + N32 N32
FRI-1 E. cloacae 1 + − 4 3
SME-1 S. marcescens 3 + − 0.25–1.5 0.5–3
SME-2 S. marcescens 1 + − 0.75 1.5
S. marcescens 1 + − 0.125 0.25
IMI-1 E. cloacae 2 + − 0.25–0.75 0.19
IMI-2 E. cloacae 1 + − 4 12
E. asburiae 1 + − N32 N32
E. asburiae 1 + − 2 1
IMI-3 E. cloacae 3 + − 12- N 32 8–32
Ambler class B carbapenemases
NDM E. coli 2 + + 16- N 32 4–32
E. coli 2 + + N32 12–16
K. pneumoniae 5 + + 4- N 32 2- N 32
P. mirabilis 1 + + 0.19 0.25
P. mirabilis 2 + + 0.064–0.19 0.19–0.5
S. enterica 1 + + 2 1
VIM E. coli 2 + + 1.5–3 0.38–1.5
K. pneumoniae 4 + + 0.25–1.5 0.25–0.75
E. cloacae 2 + + 0.25–0.38 0.19–0.25
E. cloacae 1 + + N32 12
C. freundii 2 + + 0.018 0.047
IMP E. coli 3 + + 0.38–2 0.19–0.75
K. pneumoniae 3 + + 1–1.5 0.5–1.5
E. cloacae 2 + + 0.38–0.75 0.38–0.5
S. marcescens 1 + + 4 12
Ambler class D carbapenemases
OXA-48 E. coli 5 + + 0.38–2 0.125–0.5
K. pneumoniae 4 + + 1.5- N 32 0.75–12
K. pneumoniae 1 + + N32 12
C. freundii 1 + + 0.38 0.19
C. koserii 1 + + 0.75 0.38
M. morganii 1 + +0.023 0.094
S. marcescens 1 + + 0.25 0.19
S. marcescens 1 + + 0.25 0.19
OXA-181 E. coli 1 + − 0.19 0.094
E. coli 1 − − 0.25 0.064
E. coli 1 + + 4 2
E. coli 2 + − 0.19–0.25 0.064–0.125
E. coli 1 + + 0.75 0.25
K. pneumoniae 2 − − 0.38- N 32 0.125–8
K. pneumoniae 2 + − 0.38- N 32 0.19–8
K. pneumoniae 1 + + 0.38 0.125
K. pneumoniae 1 + − 0.138 0.19
K. pneumoniae 1 + + N32 8
E. cloacae 1 + − 0.38 0.125
OXA-204 K. pneumoniae 1 + − 0.19 0.38
K. pneumoniae 1 + − 0.38 0.125
K. pneumoniae 1 + − 2 0
E. coli 4 + − 0.19–0.25 0.064–0.094
E. coli 3 − − 0.19–0.47 0.047–0.32
OXA-232 K. pneumoniae 1 + + N32 12
K. pneumoniae 1 + + N32 N32
K. pneumoniae 1 − − N32 N32
OXA-162 K. pneumoniae 2 + − 0.38 0.19
K. pneumoniae 1 + − 0.5 0.25
C. freundii 1 + − 0.38 0.19








4.2. Poor performance of the β-CARBA® test
The poor performance of the β-CARBA® test was due to the inability
to detect non-KPC Ambler class A type and most of the OXA-48-like
class D-type carbapenemase producers. This feature has been very re-
cently underlined by Bernabeu et al. (2017). Ambler A class
carbapenemases can degrade a large number of β-lactams, such as pen-
icillins, cephalosporins, carbapenems, and aztreonam and are inhibited
by clavulanic acid and tazobactam (Bush, 2013). Unlike KPC, the FRI-,
SME- and IMI-type carbapenemases possess weak hydrolyzing activity
towards broad-spectrum cephalosporinases, such as ceftazidime, cefo-
taxime, and cefepime (Dortet et al., 2015b; Naas et al., 1994; Rasmussen
et al., 1996). The carbapenemase substrate responsible for the color shift
in the β-CARBA® test is not publicly available. In light of the results of
the present work, it is possible that the substrate included in the β-
CARBA® testmight be an expanded-spectrum cephalosporin or a deriv-
ative molecule instead of a carbapenem (as RAPIDEC® CARBA NP test),
thatmay explain the inability of theβ-CARBA® test to detect the activity
of the non-KPC Ambler A class carbapenemases. Similarly to the non-
KPC Ambler class A carbapenemases, OXA-48-like producers exhibit
intrinsic and weak hydrolyzing activity towards expanded-
spectrum cephalosporins. Again, the use of an extended-spectrum
cephalosporin or a derivative molecule thereof for the detection of
carbapenemase activity may explain the poor detection of the OXA-
48-like carbapenemase production by the β-CARBA® test.
4.3. Misdetection of OXA-405 and OXA-163 ESBL by the β-CARBA® test
Of note, while the RAPIDEC® CARBA NP test assigned negative re-
sults to all the carbapenemase negative isolates, the β-CARBA® test de-
tected the non-carbapenemase OXA-48-like variants OXA-163 and
OXA-405 as carbapenemases, as previously highlighted by others
(Bernabeu et al., 2017; Compain et al., 2016). Following the study of
Compain et al. (2016), a debate arose on whether OXA-163 and OXA-
405 should or should not be classiﬁed as carbapenemases in light of
their very weak carbapenem-hydrolyzing activities (Arlet et al., 2017;
Dortet and Naas, 2017). Arlet et al. suggest that detecting low
carbapenemase producersmight be useful to predict the risk of the emer-
gence of carbapenemase-resistance in the presence of other concurrent
mechanisms (Arlet et al., 2017). On the basis of this reasoning, however,
other enzymes with weak carbapenem-hydrolyzing activity, such as the
plasmid-mediated cephalosporinases of the CMY-2-type, ACT-1-type,
and DHA-1-type should then be detected as carbapenemases as well as
overproducers (Mammeri et al., 2010). As the carbapenem-hydrolyzing
activity of these enzymes as well as that of OXA-163 and OXA-405 is so
low that it shall not compromise the therapeutic efﬁcacy of carbapenems,
we consider still appropriate to classify OXA-163 and OXA-405 as non
carbapenemases and to avoid itsmisidentiﬁcation as carbapenemase pro-
ducers. Of note, other colorimetric assays for rapid detection of
carbapenemase activity previously detected OXA-163 and OXA-405 as
non-carbapenemases (Dortet et al., 2015a).
Besides having only a marginal carbapenemase activity, OXA-163
and OXA-405 very efﬁciently hydrolyze expanded-spectrum cephalo-
sporins (Dortet et al., 2015c; Oueslati et al., 2015). This might explain
their false detection as carbapenemases in case the substrate used in
the β-CARBA® test corresponds to an expanded-spectrum cephalospo-
rin or a kind of derivative.
5. Conclusion
RAPIDEC® CARBA NP test exhibited better performances than those
of the β-CARBA® test and conﬁrmed to be a reliable tool for the rapid
Table 1 (continued)
RAPIDEC MIC (μg/ml)
β-lactamase type Species n CARBA NP® β-CARBA® ETP MEM
Non-carbapenemase producers
Wild type E. coli 1 − − 0.004 0.012
K. pneumoniae 1 − − 0.004 0.012
E. cloacae 1 − − 0.0047 0.023
M. morgannii 1 − − 0.006 0.047
P. mirabilis 1 − − 0.012 0.047
S. marcescens 1 − − 0.012 0.023
E. aerogenes 1 − − 0.064 0.023
ESBLb
CTX-M-15 E. coli 1 − − 0.006 0.016
E. cloacae 1 − − 0.019 0.047
C. freundii 1 − − 0.008 0.023
K. pneumoniae 1 − − 0.006 0.016
CTX-M E. coli 2 − − 0.006 0.014
E. cloacae 2 − − 0.25–0.5 0.047–0.094
K. pneumoniae 2 − − 0.014 0.014
CTX-M + porine defective E. coli 2 − − 0.016–1 0.016–0.019
K. pneumoniae 3 − − 0.38–2 0.016–1.5
OXA-163 K. pneumoniae 1 − + 0.38 0.5
OXA-405 S. marcescens 1 − + 0.16 0.23
GES-1 K. pneumoniae 1 − − 0.004 0.012
Cephalosporinases
AmpC overexpressed E. cloacae2 − − 0.25–0.38 0.064
M. morgannii 1 − − 0.008 0.064
AmpC overexpressed +ESBL E. cloacae 6 − − 0.19–0.38 0.023–0.094
DHA-1 E. coli 1 − − 0.016 0.016
DHA-2 K. pneumoniae 1 − − 0.25 0.094
ACC-1 E. coli 1 − − 0.016 0.023
P. mirabilis 1 − − 0.003 0.016
MIC = Minimum inhibitory concentration.
ETP = ertapenem; MEM, meropenem.
+ was considered a positive result and –was considered a negative result.
a Gray cells indicate unexpected results.








detection of CPE. The poor performances of the β-CARBA® test were
mostly due to the failure to detect the non KPC A-type carbapenemases
and most OXA-48-like producers. Failure to detect most of the OXA-
48-like producers by using the β-CARBA® test shall limit the value of
this test in geographical areas such as in Europe where those
carbapenemase producers are widely disseminated.
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